Skip to main content
OpenTrials
Completed

NCT Number: NCT02730273

The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA)

This investigation is designed to evaluate the performance (leak and comfort) as well as the participant's overall acceptance of the trial nasal mask amongst Obstructive Sleep Apnea (OSA) participants. An important factor in this investigation will be the testing of two different seal sizes on the participants (medium and large size). A total number of 12 participants who currently use nasal or nasal pillow masks will be recruited for the trial. Participants have been selected based on their anthropometric measurements collected in previous trials (CIA-103). Participants from previous NZ trials may be recruited into this trial with their consent. All the participants will be recruited from the Fisher & Paykel Healthcare Database of subjects with OSA (Ethics Reference NTY/08/06/064), Auckland District Health Board (ADHB) and New Zealand Respiratory and Sleep Institute (NZRSI).

Participants will use the trial mask in home for a period of 7 ± 3 days and also 1 overnight polysomnography session at the Fisher & Paykel Healthcare sleep lab. Baseline data will be collected from the participant during the first visit, 7 days of CPAP usage data will be downloaded and stored for analysis. The participant will use the trial device on their usual Continuous or Auto Positive Airway Pressure (CPAP/APAP) setting and device for the duration of the trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fisher & Paykel Healthcare

Auckland, 2013, New Zealand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult (18+ years of age)
  • Able to give consent
  • Apnea Hypopnea Index (AHI) ≥ 5 on diagnostic night
  • Prescribed a Continuous Positive Airway Pressure (CPAP) device after successful OSA diagnosis
  • Existing nasal or nasal pillow mask user

Exclusion criteria

  • Inability to give consent
  • Patients who are in a coma or a decreased level of consciousness.
  • Anatomical or physiological conditions making APAP therapy inappropriate (e.g. unconsolidated facial structure)
  • Commercial drivers who are investigated by New Zealand Transport Agency (NZTA)
  • Current diagnosis of CO2 retention
  • Pregnant or may think they are pregnant.

Treatment and study plan

Trial Nasal Mask

Device

Nasal mask for the treatment of obstructive sleep apnea (OSA)

Primary outcomes

  1. Objective leak data (L/min)

    Time frame: Up to 1 week in-home

    Obtained from the participant's device

  2. Subjective measurement of leak

    Time frame: Up to 1 week in-home

    Subjective Questionnaire

  3. Comfort

    Time frame: Up to 1 week in-home

    Subjective Questionnaire

  4. Stability

    Time frame: Up to 1 week in-home

    Subjective Questionnaire

  5. Draft

    Time frame: Up to 1 week in-home

    Subjective Questionnaire

  6. Noise

    Time frame: Up to 1 week in-home

    Subjective Questionnaire

  7. Objective leak data (L/min)

    Time frame: 1 night

    Obtained from the overnight polysomnography

Secondary outcomes

  1. Preference of the mask

    Time frame: Up to 1 week in-home

    Subjective Questionnaire

Sponsors and collaborators

Lead sponsor

Fisher and Paykel Healthcare

Industry

Registry information

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Apr 6, 2016
Registry last updated
Jul 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.